

CD38 (OKT10)

Type	Size	Catalog number
Unconjugated	100µg	100801
	500µg	100803
FITC	25 tests	100814
	100 tests	100815
	200 tests	100816
PE	25 tests	100824
	100 tests	100825
	200 tests	100826
APC	25 tests	100844
	100 tests	100845
	200 tests	100846
Biotin	100µg	100851

Antigen: CD38
Immunogen: Human acute lymphoblastic leukemia
Host/Isotype: Mouse, IgG1,κ
Reactivity: Human, Rhesus, Cynomolgus, Baboon
Purity: >90% pure tested via polyacrylamide gel electrophoresis (PAGE)
Formulation: PBS, pH7.2, 0.09%NaN₃ (unconjugated, Biotin)
 PBS, pH7.2, 0.09% NaN₃ and 0.2% (w/v) BSA (conjugated)
Storage: Store at 2-8°C and protected from prolonged exposure to light. **Do not freeze.**
Applications: Flow Cytometry

Application Information

Each lot of these antibodies has been pre-titrated and tested by flow cytometric analysis of human PBMCs such that 0.5µg (unconjugated, Biotin) or 5µl (conjugated) of these products are sufficient for staining 1 million cells in a 100µl staining volume or 100µl of whole blood. It is recommended to titrate antibody reactivity empirically for optimal performance. Non-human primate cross-reactivity has been validated using Caprico's purified and PE, APC, and Biotin conjugated clone OKT10 products.

Antigen Information

The clone OKT10, a mouse monoclonal antibody, recognizes a 45 kDa, type II transmembrane cell surface glycoprotein known as CD38. The CD38 antigen is expressed on pre-B lymphocytes, plasma cells, thymocytes and monocytes. CD38 also presents on activated T lymphocytes, natural killer (NK) lymphocytes, myeloblasts, and erythroblasts. Antigen expression is detected during the early stage of T- and B-lymphocyte differentiation, then lost during the intermediate stage of maturation, only to reappear during the final stage of maturation. The CD38 antigen is expressed on 90% of CD34+ cells and is not expressed on pluripotent stem cells. CD38 is expressed in T- and B-acute lymphoblastic leukemia (ALL), Burkitt's lymphoma, multiple myeloma, acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL).

References

1. Chiappelli F, et al. 1991. Int J Immunopharmacol. 13:455.
2. Flavell DJ, et al. 2001. Br J Cancer. 84:571.
3. Giorgi JV, et al. 1989. Clin Immunol Immunopathol. 52:10.
4. Lohmeyer J, et al. 1988. Br J Haematol. 69: 335.
5. Small TN, et al. 1989. Hum Immunol. 25:181.
6. Zupo S, et al. 1994. Eur J Immunol.24:1218.
7. Yoshino N, et al. 2000. Exp Anim. 49(2), 97–110.
8. Hammarlund E, et al. 2017. Nature Communications. 8: 1781.

Terms and Conditions

This product is for research use only (RUO) and not intended for diagnostic testing.